A Phase II Trial Of BEAM/Rituximab/Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Patients With CD20 Positive Non-Hodgkin's Lymphoma

0063-02-FB

RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as carmustine, cytarabine, etoposide, and melphalan, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab and combination chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy followed by autologous hematopoietic stem cell transplantation in treating patients who have B-cell non-Hodgkin's lymphoma.

2002-05-08

2005-11-01

2015-03-12

Completed

Early phase I

68

Inclusion Criteria: * Diagnosis of non-Hodgkin's lymphoma o Any B cell * CD20-positive disease * Failed prior primary induction therapy * Meets 1 of the following criteria: * Chemotherapy-refractory disease * Received at least 3 prior chemotherapy regimens * Mantle cell lymphoma * Eligible for transplantation * 19 years old and over * WHO 0-2 * Life expectancy at least 6 months * Absolute neutrophil count ≥ 1,000/mm\^3\* * Platelet count \> 50,000/mm\^3\* * Hemoglobin \> 9.0 g/dL\* o NOTE: \*Unless due to lymphomatous involvement of the bone marrow * Fertile patients must use 2 methods of effective contraception Exclusion Criteria: * No history of T-cell lymphoma * Not pregnant or nursing * No other concurrent serious disease or condition that would preclude study participation

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 68, 'type': 'ACTUAL'}}

2023-10-06